Science ❯ Medical Research ❯ Clinical Trials
Neurological Disorders Health Outcomes Ivermectin Studies GLP-1 Receptor Agonists Cardiovascular Disease Research GLP-1 Injections Long-acting Treatments Neuroscience Alzheimer's Research Public Health
Using cyclophilin A to disable mutant KRAS, the oral pill has triggered an FDA expanded‑access pathway as the maker prepares expedited approval filings.